Christopher U. Jones

Author

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

C. Jones, C.U Jones, C.U. Jones, Chirstopher U. Jones, Christopher Jones, Christopher U Jones, Christopher U Jones M.D.,, Christopher U. Jones, Christopher Uwe Jones, F. Christopher Holsinger

118

Publications

16.9K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Fox Chase Cancer Center NRG Oncology Washington University in St. Louis RTOG Foundation

About

Christopher U. Jones is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	41	7.9K
2	Health Sciences	17	21	4.9K
3	Engineering	1	1	22
4	Public Health	1	1	52
5	Biostatistics	1	1	158

Christopher U. Jones

Publications

16.7K

Citations

H-Index

Page 1

	Year	Citations
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck James A. Bonner, Paul M. Harari, J. Giralt, New England Journal of Medicine	2006	5.1K
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival James A. Bonner, Paul M. Harari, J. Giralt, The Lancet Oncology Advanced HeadNeck CancerRadiation TherapyMedicineRandomised Trial	2009	2K
A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 Karen K. Fu, Thomas F. Pajak, Andy Trotti, International Journal of Radiation OncologyBiologyPhysics Radiation MedicineAccelerated FractionationRadiation TherapyFractionation RadiotherapyMedicine	2000	1.4K
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial Maura L. Gillison, Andy Trotti, Jonathan Harris, The Lancet Radiation TherapyMedicineNasopharyngeal CancerNon-inferiority TrialCancer Treatment	2018	1.2K
Prospective Randomized Trial of Low- Versus High-Dose Radiation Therapy in Adults With Supratentorial Low-Grade Glioma: Initial Report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study Edward Shaw, Robert M. Arusell, B. W. Scheithauer, Journal of Clinical Oncology	2002	723
Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225 Nancy Lee, Jonathan Harris, Adam S. Garden, Journal of Clinical Oncology	2009	693
Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer Christopher U. Jones, Daniel Hunt, D.G. McGowan, New England Journal of Medicine	2011	691
Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413 Mack Roach, Michelle DeSilvio, C.A. Lawton, Journal of Clinical Oncology	2003	638
Multi-Institutional Trial of Accelerated Hypofractionated Intensity-Modulated Radiation Therapy for Early-Stage Oropharyngeal Cancer (RTOG 00-22) Avraham Eisbruch, Jonathan Harris, Adam S. Garden, International Journal of Radiation OncologyBiologyPhysics Radiation MedicineRadiation TherapyMedicineMulti-institutional TrialEarly-stage Oropharyngeal Cancer	2009	373
Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002) Sue S. Yom, Pedro A. Torres‐Saavedra, Jimmy J. Caudell, Journal of Clinical Oncology	2021	344

Page 1